OBJECTIVE: To investigate the role of hypercorticism in the development of compromised b-adrenergic signalling in adipocytes of mature C57BL/6J-ob/ob mice. DESIGN AND EXPERIMENTAL UNITS: Mature male ob/ob mice and their lean littermates were treated with vehicle or the speci®c glucocorticoid receptor (GR) antagonist, RU-486 (30 mg/kg bw/d) for 21 d. MEASUREMENTS: Blood glucose, serum insulin, adipocyte Glut-4 expression, adipocyte G s a expression, adenylylcyclase activation by b-adrenergic receptor (b-AR) agonists in adipocyte membranes and mRNA levels for b 1 -, b 2 -and b 3 -adrenergic receptor subtypes in adipocytes. RESULTS: RU-486 reduced blood glucose levels in ob/ob mice to levels that were not different from lean mice. RU-486 also reduced serum insulin by approximately 50% in ob/ob mice, but failed to restore depressed G s a or GLUT-4 expression in adipocytes of ob/ob mice. RU-486 produced a two-fold increase in b 3 -AR mRNA in ob/ob mice and a small but signi®cant improvement in isoprenaline-mediated adenylylcyclase activation. CONCLUSIONS: The present results indicate that glucocorticoid antagonism ameliorates diabetic symptoms of the mature ob/ob mouse, but does not lessen their obesity or fully reverse de®cient expression and function of components of the adipocyte b-adrenergic signalling cascade.
Introduction
In mice, inheritance of the ob gene from both parents produces offspring (ob/ob) that are hyperglycemic, hyperinsulinemic, and hyperphagic. At weaning (21 d) , ob/ob mice are slightly larger than their lean littermates, but by seven weeks of age are twice the size of their lean siblings. During this same period, adipose tissue from ob/ob mice undergoes a ®ve-fold expansion in size compared to lean littermates. 1 Of particular interest is the observation that adipose tissue from ob/ob mice is resistant to stimulation of lipolysis by b-adrenergic agonists. 2±4 We have recently presented evidence that this defect results from decreased expression of b 1 -and b 3 -adrenergic receptor subtypes and their cognate G protein, G s a, 5, 6 but the underlying cause for dysregulation of these genes has not been established. Recent work with cultured 3T3-F442A adipocytes showing dexamethasone-mediated downregulation of b 1 -and b 3 -adrenergic receptor subtypes 7, 8 suggests that the characteristic hypercorticism of ob/ob mice may have special relevance to the development of signalling defects in adipose tissue. The involvement of hypercorticism in the ob/ob syndrome is further supported by demonstrations that adrenalectomy ameliorates or corrects many of the symptoms of the obese/diabetic syndrome.
9±11
Studies of similar design using the glucocorticoid receptor antagonist, RU-486 have also reported improvements in some obese/diabetic syndromes in rodents, 12±14 but effects on adipocyte b-adrenergic signalling have not been reported. Thus, the purpose of the present study was to evaluate whether glucocorticoid receptor blockade in fully developed obesity would reverse the documented defects in adipocyte badrenergic signalling. Using mature ob/ob mice fully expressing the obese/diabetic syndrome, it is shown that RU-486 ameliorated overt diabetes, but failed to correct their obesity or the compromised responsiveness of the adipocyte b-adrenergic signalling system.
Materials and methods

Materials
N-tris(hydroxylmethyl)methyl-2-aminoethanesulfonic acid buffer (TES   2   ) , sucrose, mercaptoethanol, ethylenediamine tetraacetic acid (EDTA), N,N H -diallyltartardiamide (DATD), dithiothreitol (DTT), bovine serum albumin (BSA), leupeptin, phenylmethylsulfonyl¯uoride (PMSF), adenosine triphosphate (ATP), adenosine, soybean trypsin inhibitor and other common chemicals were from Sigma Chemicals, St Louis, USA. Immobilon-P PVDF membranes and 10 000 MW cutoff low protein-binding membranes were from Millipore Corp., Bedford, MA, USA. Na[ 125 I] was purchased from Dupont NEN Radiochemicals, Boston, MA, USA. The glucocorticoid receptor antagonist, RU-486 was a gift of Roussel Uclaf (Romainville, France). Anti-peptide antiserum against the Glut-4 glucose transporter was from Calbiochem/Novabiochem (San Diego, CA, USA). Radioimmunoassay (RIA) kits for rodent insulin were purchased from Linco Research Labs (St. Charles, MO, USA). The b 3 -adrenergic receptor selective agonist, BRL-37344A was a gift from SmithKline Beecham Pharmaceuticals (Surrey, UK).
Experimental animal protocol
Lean (/) and obese (ob/ob) C57BL6J mice were obtained from Jackson Labs (Bar Harbor, ME, USA) at eight weeks of age and equal numbers of mice of each phenotype were randomly assigned to one of two groups. One group of animals in each phenotype was injected subcutaneously with RU-486 (30 mg/kg bw/d) for 21 d while the other group in each phenotype received vehicle (arachis oil). This vehicle and dosage have previously been shown to produce effective glucocorticoid receptor blockade in rodents. 14, 15 All animals were killed on day 22 and blood samples were obtained for assay of glucose and insulin as previously described. 16 
Isolation of adipocytes
Adipocytes were prepared from the epididymal fat pads of male mice as previously described by Rodbell 17 with slight modi®cation. 5, 18 The cells were washed and resuspended in Krebs-Ringer-Hepes (KRH) buffer containing 1 mM CaCl 2 .
Preparation of plasma membranes
Cells were broken in a Dounce homogenizer in hypotonic buffer containing 10 mM TES (pH 7.0) and 1 mM EDTA. Unbroken cells and nuclei were removed by an initial low speed spin at 300 g, and crude membranes were collected from the supernatant by a 20 min spin at 48 000 g. The pelleted membranes were resuspended in 10 mM TES (pH 7.5) containing 0.25 M sucrose, followed by puri®cation of plasma membranes by aqueous two-phase partition with Dextran and polyethylene glycol as described previously. 5, 19 The puri®ed plasma membranes were resuspended at 1 mg/ml in 25 mM Hepes (pH 7.4) containing 140 mM NaCl, 40 mM leupeptin, 1 mg/ml soy bean trypsin inhibitor and 1 mM EDTA, then stored at À80 C.
Antisera for Western blotting
Antiserum was raised against the C-terminal decapeptide of G s a 20,21 as previously described. 22 The Immunoglobulins (IgGs) were puri®ed, standardized to 6 mg/ml and characterized with respect to titer, speci®city and cross reactivity using lysates from bacteria transformed with the cDNA for each of the guanine nucleotide binding regulatory G proteins. 22, 23 The anti-G s a IgGs were used at a ®nal concentration of 0.75 mg/ml. The antiserum against Glut-4 was used at a ®nal dilution of 1:1000.
Solubilization of adipocyte membranes
Puri®ed plasma membranes were solubilized on ice for 1 h in 20 mM Tris, 1 mM EDTA, 1 mM DTT, 100 mM NaCl and 0.9% Na cholate (pH 8.0). The supernatant was collected after centrifugation at 13 000 g for 5 min at 4 C and protein was carefully assayed using the Biorad detergent compatible protein assay. Bovine serum albumin made up in the solubilization buffer was used as the standard. In initial experiments, solubilized membranes from each phenotype were resolved by SDS-PAGE and visualized by Coomassie staining. The Coomassie-stained gels were scanned on a Molecular Dynamics (Sunnyvale, CA, USA) densitometer at 50 mm scanning resolution to establish that equivalent amounts of protein from each phenotype would be compared in subsequent Western blots for Glut-4 and G S a.
Western blotting procedure
Solubilized plasma membranes were resolved by SDS-polyacrylamide gel electrophoresis (12.5% acrylamide, 0.051% DATD), and transferred by electrophoresis to Immobilon-P (Millipore Corp., Bedford, MA, USA) PVDF membranes. 5, 24 Following the procedure of Mumby et al, 25 the PVDF membranes were probed with the Glut-4 or G S a antisera described RU-486 ameliorates diabetes TW Gettys et al above, and the bands were detected with 125 I-labeled goat anti-rabbit IgG (1 6 10 6 cpm/ml). The membranes were washed, blotted dry and exposed overnight to Kodak XAR ®lm with intensifying screens. The respective autoradiograms were scanned by laser densitometry (Molecular Dynamics, Inc.), and the integrated volume of the appropriate band(s) on each blot were determined using Imagequant Software (Molecular Dynamics, Inc.). The densitometric units were compared using ANOVA.
Northern blotting of b-adrenergic receptor subtypes
The epididymal fat pads were removed and homogenized in 4 ml of cold guanidinium thiocyanate buffer, followed by isolation of total cellular RNA by cesium chloride gradient centrifugation. RNA was denatured and fractionated on 1.2% agarose gels, followed by blotting onto nylon membranes. The cDNA fragments from the three b-adrenergic receptor subtypes used as hybridization probes were prepared as described by Collins et al 6 and radiolabeled by nick translation in the presence of a-[
Blots were hybridized and washed as previously described 6 and the relative abundance of the receptor subtypes was normalized by reprobing with a cDNA cyclophilin probe. The integrated volumes of the transcripts at 2.4 kb (b 1 -AR), 2.2 kb (b 2 -AR), and 2.1, 2.6, and 3.5 kb (b 3 .-AR) were determined using a molecular dynamics phosphoimager and compared by ANOVA.
Adenylylcyclase assay
Adenylylcyclase activity was determined in puri®ed plasma membranes by methods described previously. 5, 26, 27 In brief, 10 mg of puri®ed plasma membranes were incubated for 10 min at 30 C in a buffer containing 50 mM TES (pH 7.4), 4.0 mM MgCl 2 , 2 mM creatine phosphate, 25 U/ml creatine phosphokinase, 100 mM ATP, 10 mM GTP and 1 U/ml of adenosine deaminase. The reaction was conducted in a ®nal volume of 300 ml and initiated by adding 50 ml of the membrane preparation to each incubation tube. Reactions were terminated by adding 50 ml of cold 25% TCA and centrifuging for 15 min at 2500 6 g. Cyclic AMP formed in the reaction was measured in the supernatant by RIA according to methods described previously.
5 Dose-response curves were characterized using the four parameter logistic ogive in relation to log dose as described previously. 5 
Results
Growth and serum characteristics
The initial body weights of mice within each phenotype were similar at the beginning of the study and RU-486 treatment had no effect on the growth of ob/ ob mice during the three week experiment ( Table 1) . Vehicle-treated lean mice gained 60% less weight than either ob/ob group during the study ( Table 1) , and RU-486 treated lean mice gained only half as much weight as the lean control group during the same period (P`0.05). The weight of epididymal fat pads collected when killed, paralleled body weight among the groups (data not shown).
Insulin concentrations in serum collected at sacri®ce were 10-fold higher in vehicle-treated ob/ob compared to lean mice (Table 1 ) and glucose levels were signi®cantly higher in the ob/ob group as well (P`0.05). Treatment of lean mice with RU-486 had no effect on serum insulin or glucose concentrations, but in ob/ob mice the GR antagonist fully corrected hyperglycemia and reduced serum insulin concentrations by nearly 50% ( Table 1) .
Expression of GLUT-4 and G proteins
Initial experiments were conducted to establish that equivalent amounts of adipocyte membrane protein were being loaded onto gels for each phenotype and treatment group. These studies were necessary to guarantee that denominators for subsequent comparisons were the same, and initial gels were Coomassie stained and evaluated by densitometry prior to proceeding with Western blots. Expressed in densitometric units, the means of replicate extracts (n 3) for each treatment group and phenotype were similar across the groups (Lean-Control, 6594 AE 38; Lean-RU-486, 6814 AE 42; ob/ob-Control 6505 AE 45; ob/ ob-RU-486, 6938 AE 51).
In the next series of experiments, immunoblots were prepared using each of three sets of extracts for each treatment group and phenotype, and probed with antipeptide antisera for G s a and GLUT-4. Representative blots for G s a and GLUT-4 are presented in Figure 1 , along with the accompanying summary data for the densitometric analysis presented below each blot.
The expression of both splice variants of G s a (43 and 48 kDa) was reduced 40±50% (P`0.05) in vehicle-injected ob/ob compared to lean mice (Figure 1a) . GLUT-4 expression levels were also signi®cantly Figure 1a) , and despite the correction of hyperglycemia by RU-486 in ob/ob mice, it did not affect expression of the GLUT-4 glucose transporter in either phenotype (Figure 1b) .
Levels of mRNA for b-adrenergic receptor subtypes
Levels of mRNA for the three b-adrenergic receptor (b-AR) subtypes were compared in total RNA prepared from epididymal fat pads from mice in each phenotype and treatment group. A single transcript of 2.4 kb was the primary transcript detected with the b 1 -AR probe, although a second band at 2.3 kb was evident in the lean groups ( Figure 2 ). The relative abundance of the 2.4 kb transcript in each treatment group, corrected for expression of cyclophilin, was signi®cantly lower in the ob/ob groups compared to lean groups (P`0.05; Figures 2 and 3a) . Although RU-486 had no effect on b 1 -AR mRNA levels in lean mice, it produced a small but signi®cant reduction in mRNA levels in ob/ob mice (P`0.05; Figure 3a) .
The relative abundance of b 2 -AR transcripts did not differ between lean and ob/ob mice in the control groups, and RU-486 did not alter expression in the lean group. However, as with the b 1 -AR, RU-486 produced a small but signi®cant reduction in b 2 -AR mRNA levels in ob/ob mice (Figures 2 and 3b) . Transcripts for the b 3 -AR were expressed at high levels in vehicle-injected lean mice and RU-486 did not alter mRNA levels for this receptor in lean mice. In contrast, b 3 -AR mRNA levels in vehicle-injected ob/ob mice were extremely low, averaging only 8% of levels observed in lean mice (Figures 2 and 3) . Treatment of ob/ob mice with RU-486 produced a signi®cant two-fold increase in b 3 -AR transcripts (P`0.05), but the levels were still quite low in comparison to the lean groups.
Functional activity of b-adrenergic receptors
The functional signi®cance of treatment and phenotype-dependent changes in b-AR mRNA was evaluated by assaying adenylylcyclase activity in adipocyte membranes stimulated with b-AR agonists. The adrenergic agonists chosen for these studies included isoprenaline, a potent yet nonselective ligand for b 1 -, b 2 -, and b 3 -ARs. 28 The aim of using isoprenaline was to provide an estimate of the composite effect of changes in the entire population of b-ARs. The ligand BRL-37344 was also used because it is selective for the b 3 -AR and has relatively weak af®nity for b 1 -and b 2 -ARs. 28, 29 These two ligands provided the tools to examine how changes in expression of the three receptor subtypes affected the responsiveness of the adipocyte b-adrenergic signalling system. 
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Comparison of the concentration-response curves for each group using BRL-37344 and isoprenaline are presented in Figure 4 . The response curves were characterized by ®tting a four parameter logistic ogive to each response surface as described previously. 5, 18, 26, 30 The potency of adenylyl cyclase activation by the b 3 -selective agonist, BRL37344 ranged from 90±209 nM among the groups and was unaffected by either phenotype or treatment with RU-486. However, the essentially¯at response surface in the ob/ob groups made for poor precision in point estimates of potency. Poor precision was also noted in estimates of ef®cacy in the ob/ob groups. Thus, although the estimates of ef®cacy suggest that maximal adenylylcyclase activation was greater in RU-486-treated ob/ob mice (56.0 AE 17.6 pmol cAMP/min/mg) compared to control ob/ob mice (46.9 AE 12.6 pmol cAMP/min/mg), the large standard errors attached to these point estimates precluded detection of a difference (Figure 4a ). There is also a suggestion in Figure 4a that the ef®cacy of BRL- RU-486 ameliorates diabetes TW Gettys et al 37344 was increased in RU-486-treated lean mice, but that conclusion was not supported by the data. In contrast, the ef®cacy of BRL-37344 is clearly higher in lean groups compared to ob/ob groups (P`0.05, Figure 4a ). The latter ®nding is consistent with the almost complete absence of b 3 -AR mRNA in the ob/ob groups (Figure 2) .
In contrast to BRL-37344, isoprenaline produced a more discernible activation of adenylylcyclase in both ob/ob groups (Figure 4b ). This arises from isoprenaline's activation of all three b-AR subtypes and their respective contributions to activating adenylylcyclase. Potency estimates for isoprenaline were in the low micromolar range (0.86±2.79 mM) in both lean and ob/ ob groups and did not differ with respect to either phenotype or treatment. By comparison, the ef®cacy of isoprenaline was signi®cantly higher in lean compared to ob/ob groups (Figure 4b ). And as noted with BRL-37344, there is a suggestion that RU-486 increased the ef®cacy of isoprenaline in both phenotypes (Figure 4b ). Maximal adenylyl cyclase activation was signi®cantly higher (P`0.05) in RU-486-treated ob/ob mice (156 AE 20.4 pmol cAMP/min/mg) compared to control ob/ob mice (104 AE 5.4 pmol cAMP/min/mg), but the effect of RU-486 was not signi®cant in lean mice (Figure 4b) .
Additional experiments were conducted to determine whether expression of adenylylcyclase activity was modi®ed by treatment with RU-486 and contributed indirectly to differences in ef®cacy of b-adrenergic agonists. Basal adenylyl cyclase activity did not differ between vehicle-injected lean (34.7 AE 2.1 pmol cAMP/min/mg) and ob/ob mice (30.8 AE 1.6 pmol cAMP/min/mg), but was increased by RU-486 in both lean (42.3 AE 2.3 pmol cAMP/min/mg) and ob/ob (36.9 AE 0.9 pmol cAMP/min/mg) phenotypes (P`0.05). In contrast, maximal adenylyl cyclase activation by a combination of forskolin and Mn 2 did not differ among any of the four groups ( Figure 5 ).
Discussion
Glucocorticoids are ubiquitous regulators of gene transcription, and excess production immediately prior to weaning, precedes, and is essential for, development of non-insulin dependent diabetes mellitus (NIDDM) in the ob/ob mouse. Adrenalectomy prior to or at weaning ameliorates the severity of obesity and prevents the development of diabetes in the ob/ob mouse. 31±34 Moreover, the syndrome can be recreated in adrenalectomized animals given exogenous glucocorticoid. 34 The bene®cial effects of adrenalectomy are dependent on timing, since adrenalectomy at later ages had little effect on fat accretion. 31 Similar conclusions were reached in studies using the glucocorticoid receptor antagonist, RU-486, in that receptor blockade at or near weaning prevented development of the obese phenotype, while administration at later ages was ineffective. 12, 14 Findings from the present study are consistent with both sets of studies in the sense that RU-486 treatment did not lessen the severity of obesity in ob/ob mice, but did correct their hyperglycemia and reduce insulin concentrations by 50%. One might question why hyperinsulinemia persisted despite the correction of hyperglycemia. Two distinct but contributing mechanisms are postulated. First, glucocorticoids have been linked to insulin resistance through negative effects on expression of early components in the insulin signalling cascade. 35, 36 By antagonizing this effect, it is likely that RU-486 improved insulin responsiveness in target issues and improved peripheral glucose uptake. However, if some degree of insulin resistance persisted, moderately high insulin levels would be required to maintain the euglycemic state. Second, hypertrophy and hyperplasia of pancreatic b-cells have been well documented in ob/ob mice, 34 and recent studies demonstrate that pancreatic islets from ob/ob mice were hypersensitive to acetylcholinemediated insulin secretion. 37, 38 Thus, despite an expected RU-486 mediated reduction in parasympathetic tone to the pancreas, 39 it is easy to envision how an increased number of hypersensitive secretory cells may have maintained elevated basal insulin secretion. Indeed, recent work has shown that intravenous atropine, which would block vagal drive to pancreatic bcells, reduced both basal and glucose-mediated insulin secretion in fatty Zucker rats. 39 Although the present studies do not address the mechanism of RU-486's bene®cial effects, the reduction in serum insulin and correction of hyperglycemia are consistent with previous reports and the expected response to effective glucocorticoid receptor blockade in these mice.
Previous studies have detected decreased expression of the GLUT-4 glucose transporter in adipocytes from rodents and humans with NIDDM, 40±43 but the mechanism of this decrease has not been identi®ed. GLUT-4 is one of a number of genes whose expression is dramatically increased after clonal expansion ceases and terminal differentiation of adipocytes is 
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TW Gettys et al initiated. 44 Thus, if hyperinsulinemia is responsible for decreasing adipocyte GLUT-4 in the present study, the partial lowering of serum insulin by RU-486 may have been offset by improved insulin responsiveness such that the insulin signal was not diminished. The present studies were not designed to address this particular point, but they do suggest that hypercorticism is not the sole or primary signal for decreased GLUT-4 expression in adipocytes of ob/ob mice.
Hypercorticism in the ob/ob mouse has special relevance to our observed changes in b-ARs since glucocorticoids have been shown to differentially affect b-AR expression in a number of systems. 45, 46 For example, exposure of differentiating 3T3-F442A preadipocytes to dexamethasone induces reciprocal changes in expression patterns of b 2 -ARs vs b 1 -ARs. 47 Perhaps more importantly, dexamethasone decreased b 3 -AR mRNA and produced a corresponding decrease in activation of adenylylcyclase. 7 Thus, the situation in 3T3-F442A adipocytes treated with dexamethasone is quite similar to the observed patterns of b-AR subtype expression in 12 week old ob/ ob mice. 6 These similarities prompted us to test whether glucocorticoid receptor blockade would increase expression of b 3 -and b 1 -AR subtypes and correct the compromised function of the b-adrenergic signalling cascade in adipocytes from mature ob/ob mice.
The b 3 -AR is expressed in large stoichiometric excess compared to the b 1 -and b 2 -ARs in adipose tissue from lean mice. 6 In contrast, b 3 -AR is essentially absent in adipocytes from mature ob/ob mice. 6 Based on the observations of Feve et al, 7 we expected to ®nd that RU-486 would increase b 3 -AR expression in ob/ob mice. This expectation was ful®lled in part but the increase in b 3 -AR expression was modest (two-fold). One interpretation is that b 3 -AR expression is being repressed by additional components of the ob/ob syndrome not corrected by RU-486. An obvious candidate is insulin because hyperinsulinemia occurs immediately after weaning in ob/ob mice, 1 and insulin was shown to decrease mRNA and decrease function of the b 3 -AR in 3T3-F442A adipocytes. 48 Thus, the failure of RU-486 to fully correct hyperinsulinemia in ob/ob mice may have prevented complete restoration of b 3 -AR expression. Given that adrenalectomy or RU-486 treatment at younger ages is more effective in correcting hyperinsulinemia in obese rodents, 10, 11, 14, 31 it will be interesting to see if a similar experimental approach will fully restore b 3 -AR expression. Recent work has shown that b 3 -AR expression is also modulated by thyroid status. 49 Therefore, hypothyroidism may contribute to compromised b 3 -AR expression in ob/ob mice. Although not evaluated, it seems unlikely that glucocorticoid receptor blockade would correct the hypothyroidism of ob/ ob mice.
Our previous work has shown that b 1 -AR mRNA is also reduced in adipose tissue from ob/ob mice. 6 Similar alterations were noted in control ob/ob mice in the present study and RU-486 treatment did not correct this decrease in b 1 -AR mRNA. In fact, RU-486 produced a small but signi®cant further reduction in b 1 -AR mRNA in the ob/ob group, suggesting that glucocorticoids may not be the primary cause for the difference in levels between lean and ob/ob mice. Considering their hypercorticism and previous work showing that the b 2 -AR is positively regulated by glucocorticoids, 46 an increase in b 2 -AR expression in ob/ob might be expected. However, in agreement with our previous work, 6 b 2 -AR mRNA did not differ between lean and ob/ob mice. These ®ndings suggest that the b 2 -AR may be responding to glucocorticoids and another counter regulatory signal. The small but signi®cant reduction in b 2 -AR mRNA in RU-486-treated ob/ob supports this suggestion in part. Since the b 2 -AR is also positively regulated by testosterone, 50 the poor pituitary support for testicular function in ob/ob mice 34 may be counteracting the stimulatory effects of glucocorticoids on b 2 -AR expression. The effect of RU-486 on testosterone levels was not evaluated in the present study, but as with thyroid hormones, it seems unlikely that the antagonist would signi®cantly alter testicular function.
In addition to blocking glucocorticoid receptors, RU-486 was also shown to stimulate oxygen consumption through increased sympathetic activation of brown adipose tissue (BAT). 13 This effect was blocked by denervation of BAT or b-AR blockade, 13 suggesting that the bene®cial effects of RU-486 were mediated through b-ARs. If this suggestion is correct, reduced expression of b-ARs in BAT would compromise the ability of BAT to respond to increased sympathetic stimulation. Given our previous work demonstrating the very low level b 3 -AR mRNA in BAT, 6 RU-486 may fail to moderate obesity in mature ob/ob mice because BAT is unable to respond to increased sympathetic tone. Moreover, we have shown that b 3 -AR expression is only moderately reduced in white adipose tissue of ob/ob mice after weaning, but substantially absent in mature ob/ob mice. If a similar age-dependent decrease in b 3 -AR expression occurs in BAT, this may explain why RU-486 is much less effective in ameliorating obesity in mature vs weanling ob/ob mice. Although Hardwick et al 13 did not evaluate the effect of age, the authors found that RU-486-mediated increases in oxygen consumption were signi®cantly compromised in male fatty Zucker rats. This ®nding supports the concept that reduced b 3 -AR expression in BAT may alter the ability of this tissue to respond to changes in sympathetic out¯ow.
The results of the present study indicate that the antiglucocorticoid RU-486 ameliorates diabetic symptoms in mature ob/ob mice, but does not reduce their obesity. Moreover, RU-486 produced a modest twofold increase in b 3 -AR mRNA and responsiveness of the b-AR signalling system in white adipose tissue. Considered together, the present work suggests that hypercorticism in adult ob/ob mice is not singularly responsible for depression of b 3 -AR expression in epididymal adipose tissue.
